REMIND: An Investigator Initiated Study Testing the Feasibility of Maintenance Radiotherapy for Patients with Newly Diagnosed Glioblastoma

This study is testing whether a single additional treatment of radiation therapy, called maintenance radiotherapy, is safe and feasible for adults who have recently been diagnosed with glioblastoma (GBM). Participants will first receive their usual treatment for GBM, including surgery, radiation therapy, and the chemotherapy drug temozolomide. About one month after completing standard radiation therapy, participants will receive one additional treatment of radiation therapy. The study will also look at changes in certain immune cells before and after the additional radiation treatment. Participants will continue their usual follow-up care every 2 to 4 months for up to 5 years after the additional treatment.